Study of Bafetinib as Treatment for Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

December 31, 2011

Study Completion Date

April 30, 2013

Conditions

B-Cell Chronic Lymphocytic Leukemia

Interventions

DRUG

bafetinib

250 mg orally twice daily. Treatment continues until clinically significant disease progression or unacceptable toxicity is documented.

Trial Locations (2)

UT M.D. Anderson Cancer Center, Houston

City of Hope National Medical Center, Duarte